©2014 Baishideng Publishing Group Inc.
World J Clin Cases. Nov 16, 2014; 2(11): 668-675
Published online Nov 16, 2014. doi: 10.12998/wjcc.v2.i11.668
Published online Nov 16, 2014. doi: 10.12998/wjcc.v2.i11.668
Table 3 Ongoing clinical studies in idiopathic pulmonary fibrosis patients
| Target | Potential molecular target | Ongoing clinical study |
| Signals from other cells | Interleukin 13 | Lebrikizumab NCT01872689 |
| Autocrine signals | Connective tissue growth factor | Tralokinumab NCT02036580 |
| FG-3019 NCT01890265 | ||
| Cell surface | Lysophosphatidic acid receptor Lysyl oxidase LOXL2 CD20 Androgen receptor | Lysophosphatic acid receptor antagonist-NCT01766817 Simtuzumab NCT01769196 Rituximab NCT01969409 Nandrolone decanoate NCT02055456 |
| Plasma membrane-cytosol interface | Phosphoinositol kinase PI3K | Phosphoinositol kinase PI3K inhibitor NCT01725139 |
| Cytosol signal transducers | Αvβ6 integrin | STX-100 NCT01371305 |
| Nucleus | None | |
| Stem cells | Autologous adipose-derived adult stem cells NCT02135380 | |
| Autologous mesenchymal bone marrow-derived stem cells NCT01919827 | ||
| Allogenic human mesenchymal stem cells NCT02013700 |
- Citation: Sterclova M, Vasakova M. Promising new treatment targets in patients with fibrosing lung disorders. World J Clin Cases 2014; 2(11): 668-675
- URL: https://www.wjgnet.com/2307-8960/full/v2/i11/668.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v2.i11.668